Delivery Order SPE2DB22D2007-SPE2DB25FJ5AV
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency valued at approximately $50.9K for Dupixent 300 mg/2 ml pen injectors. The award, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, was competitively awarded without set-aside restrictions under a firm fixed-price arrangement. This delivery order is issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $26,119.30 for Dupixent 300 mg/2 ml pen (2 ml) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-set-aside, competitively awarded contract. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency (DLA) for Dupixent 200 mg/1.14 ml pen auto-injectors. The contract is valued at $1,935.84 with a firm fixed price structure and an ultimate completion date of August 5, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,862.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $16,770.06 by the Defense Logistics Agency (DLA) on September 11, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors. This is a firm fixed-price, non-set-aside competitive award with an ultimate completion date of September 12, 2025. The pharmaceutical will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and distribution hub for federal...
- The Defense Logistics Agency awarded a $26,459.82 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors, with an ultimate completion date of September 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at approximately $24,000 on August 25, 2025, by the Department of Defense Medical Supply Chain to supply Dupixent 300 mg/2 mL pen injectors. The contract is non-competitive, firm fixed-price, and carries an ultimate completion date of August 26, 2025, with performance occurring at the vendor's Conshohocken facility. This delivery order is executed under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for Dupixent 300 mg/2 ml pen (2 ml) with a ceiling value of $9,466.60. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 13, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $3,418.92 by the Defense Logistics Agency for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through December 2026 that serves as a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $61,126.46 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 31, 2025, with an ultimate completion date of August 1, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5AVDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency (DLA) valued at $46,171.82 for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of September 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. Dupixent (dupilumab) is a monoclonal antibody therapy used to treat various inflammatory conditions, making this order part of the company's comprehensive pharmaceutical support to federal military and veteran healthcare systems. This delivery order exemplifies AmerisourceBergen's established role as a critical federal medical supply vendor, particularly within the DLA's Medical Supply Chain. The award reflects the company's capacity to fulfill specialized pharmaceutical procurement requirements through open competition and demonstrates its versatility in delivering both high-value specialty medications and medical supplies across multiple therapeutic domains. The DLA Pharmaceutical Prime Vendor Global Program represents a strategic sourcing approach for military healthcare procurement, with AmerisourceBergen positioned as a primary supplier supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.2k | 9/17/25 |